|
1
|
Arifi S, Elmesbahi O and Amarti Riffi A:
Primary signet ring cell carcinoma of the colon and rectum. Bull
Cancer. 102:880–888. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Fu J, Wu L, Jiang M, Tan Y, Li D, Chen F,
Jiang T and Du J: Signet ring cell carcinoma of resectable
metastatic colorectal cancer has rare surgical value. J Surg Oncol.
114:1004–1008. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cabibi D, Calascibetta A, Aragona F,
Martorana A, Campione M and Sanguedolce R: Differing expression of
metalloprotease and of adhesion molecules in signet-ring cell and
intestinal colorectal carcinoma. Anticancer Res. 29:4417–4422.
2009.PubMed/NCBI
|
|
4
|
Bellan A, Cappellesso R, Lo Mele M, Peraro
L, Balsamo L, Lanza C, Fassan M and Rugge M: Early signet ring cell
carcinoma arising from colonic adenoma: The molecular profiling
supports the adenoma-carcinoma sequence. Hum Pathol. 50:183–186.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wistuba II, Behrens C, Albores-Saavedra J,
Delgado R, Lopez F and Gazdar AF: Distinct K-ras mutation pattern
characterizes signet ring cell colorectal carcinoma. Clin Cancer
Res. 9:3615–3619. 2003.PubMed/NCBI
|
|
6
|
Korphaisarn K, Morris V, Davis JS, Overman
MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti
M, et al: Signet ring cell colorectal cancer: Genomic insights into
a rare subpopulation of colorectal adenocarcinoma. Br J Cancer.
121:505–510. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Liang Z, Yan D, Li G and Cheng H: Clinical
analysis of primary colorectal signet-ring cell carcinoma. Clin
Colorectal Cancer. 17:e39–e44. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Nitsche U, Friess H, Agha A, Angele M,
Eckel R, Heitland W, Jauch KW, Krenz D, Nüssler NC, Rau HG, et al:
Prognosis of mucinous and signet-ring cell colorectal cancer in a
population-based cohort. J Cancer Res Clin Oncol. 142:2357–2366.
2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Börger ME, Gosens MJ, Jeuken JW, van
Kempen LC, van de Velde CJ, van Krieken JH and Nagtegaal ID: Signet
ring cell differentiation in mucinous colorectal carcinoma. J
Pathol. 212:278–286. 2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chen JS, Hsieh PS, Chiang JM, Yeh CY, Tsai
WS, Tang R, Changchien CR and Wu RC: Clinical outcome of signet
ring cell carcinoma and mucinous adenocarcinoma of the colon. Chang
Gung Med J. 33:51–57. 2010.PubMed/NCBI
|
|
11
|
Hyngstrom JR, Hu CY, Xing Y, You YN, Feig
BW, Skibber JM, Rodriguez-Bigas MA, Cormier JN and Chang GJ:
Clinicopathology and outcomes for mucinous and signet ring
colorectal adenocarcinoma: Analysis from the national cancer data
base. Ann Surg Oncol. 19:2814–2821. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Song IH, Hong SM, Yu E, Yoon YS, Park IJ,
Lim SB, Kim JC, Yu CS and Kim J: Signet ring cell component
predicts aggressive behaviour in colorectal mucinous
adenocarcinoma. Pathology. 51:384–391. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Fukata K, Yuasa N, Takeuchi E, Miyake H,
Nagai H, Yoshioka Y and Miyata K: Clinical and prognostic
differences between surgically resected right-sided and left-sided
colorectal cancer. Surg Today. 50:267–274. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Anthony T, George R, Rodriguez-Bigas M and
Petrelli NJ: Primary signet-ring cell carcinoma of the colon and
rectum. Ann Surg Oncol. 3:344–348. 1996.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Bae JM, Kim MJ, Kim JH, Koh JM, Cho NY,
Kim TY and Kang GH: Differential clinicopathological features in
microsatellite instability-positive colorectal cancers depending on
CIMP status. Virchows Arch. 459:55–63. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Alvi MA, Loughrey MB, Dunne P, McQuaid S,
Turkington R, Fuchs MA, McGready C, Bingham V, Pang B, Moore W, et
al: Molecular profiling of signet ring cell colorectal cancer
provides a strong rationale for genomic targeted and immune
checkpoint inhibitor therapies. Br J Cancer. 117:203–209.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tajiri K, Sudou T, Fujita F, Hisaka T,
Kinugasa T and Akagi Y: Clinicopathological and corresponding
genetic features of colorectal signet ring cell carcinoma.
Anticancer Res. 37:3817–3823. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yalcin S and Onguru O: BRAF mutation in
colorectal carcinomas with signet ring cell component. Cancer Biol
Med. 14:287–292. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Guinney J, Dienstmann R, Wang X, de
Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda
G, Angelino P, et al: The consensus molecular subtypes of
colorectal cancer. Nat Med. 21:1350–1356. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Lenz HJ, Ou FS, Venook AP, Hochster HS,
Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD,
Zemla T, et al: Impact of consensus molecular subtype on survival
in patients with metastatic colorectal cancer: Results from
CALGB/SWOG 80405 (Alliance). J Clin Oncol. 37:1876–1885.
2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Stintzing S, Wirapati P, Lenz HJ,
Neureiter D, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser
F, Al-Batran S, Heintges T, et al: Consensus molecular subgroups
(CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI
plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Ann Oncol. 30:1796–1803. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mooi JK, Wirapati P, Asher R, Lee CK,
Savas P, Price TJ, Townsend A, Hardingham J, Buchanan D, Williams
D, et al: The prognostic impact of consensus molecular subtypes
(CMS) and its predictive effects for bevacizumab benefit in
metastatic colorectal cancer: Molecular analysis of the AGITG MAX
clinical trial. Ann Oncol. 29:2240–2246. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Eide PW, Bruun J, Lothe RA and Sveen A:
CMScaller: An R package for consensus molecular subtyping of
colorectal cancer pre-clinical models. Sci Rep.
7(16618)2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Almagro UA: Primary signet-ring carcinoma
of the colon. Cancer. 52:1453–1457. 1983.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Secco GB, Fardelli R, Campora E, Lapertosa
G, Gentile R, Zoli S and Prior C: Primary mucinous adenocarcinomas
and signet-ring cell carcinomas of colon and rectum. Oncology.
51:30–34. 1994.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Belli S, Aytac HO, Karagulle E, Yabanoglu
H, Kayaselcuk F and Yildirim S: Outcomes of surgical treatment of
primary signet ring cell carcinoma of the colon and rectum: 22
cases reviewed with literature. Int Surg. 99:691–698.
2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nitsche U, Zimmermann A, Spath C, Müller
T, Maak M, Schuster T, Slotta-Huspenina J, Käser SA, Michalski CW,
Janssen KP, et al: Mucinous and signet-ring cell colorectal cancers
differ from classical adenocarcinomas in tumor biology and
prognosis. Ann Surg. 258:775–783. 2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hugen N, Verhoeven RH, Lemmens VE, van
Aart CJ, Elferink MA, Radema SA, Nagtegaal ID and de Wilt JH:
Colorectal signet-ring cell carcinoma: Benefit from adjuvant
chemotherapy but a poor prognostic factor. Int J Cancer.
136:333–339. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kim D, Kim SY, Lee JS, Hong YS, Kim JE,
Kim KP, Kim J, Jang SJ, Yoon YK and Kim TW: Primary tumor location
predicts poor clinical outcome with cetuximab in RAS wild-type
metastatic colorectal cancer. BMC Gastroenterol.
17(121)2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Tung YS, Wu SC and Chen CP: Primary signet
ring cell carcinoma of colorectum: An age- and sex-matched
controlled study. Am J Gastroenterol. 91:2195–2199. 1996.PubMed/NCBI
|
|
31
|
He J, Shin H, Wei X, Kadegowda AK, Chen R
and Xie SK: NPC1L1 knockout protects against colitis-associated
tumorigenesis in mice. BMC Cancer. 15(189)2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Hu X, Matsumoto K, Jung RS, Weston TA,
Heizer PJ, He C, Sandoval NP, Allan CM, Tu Y, Vinters HV, et al:
GPIHBP1 expression in gliomas promotes utilization of
lipoprotein-derived nutrients. Elife. 8(e47178)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yang DA, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Hwang WL, Yang MH, Tsai ML, Lan HY, Su SH,
Chang SC, Teng HW, Yang SH, Lan YT, Chiou SH and Wang HW: SNAIL
regulates interleukin-8 expression, stem cell-like activity, and
tumorigenicity of human colorectal carcinoma cells.
Gastroenterology. 141:279–291, 291.e1-e5. 2011.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Gasiulė S, Dreize N, Kaupinis A, Ražanskas
R, Čiupas L, Stankevičius V, Kapustina Ž, Laurinavičius A, Valius M
and Vilkaitis G: Molecular insights into miRNA-driven resistance to
5-fluorouracil and oxaliplatin chemotherapy: miR-23b modulates the
epithelial-mesenchymal transition of colorectal cancer cells. J
Clin Med Res. 8(2115)2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Bhangu A, Wood G, Mirnezami A, Darzi A,
Tekkis P and Goldin R: Epithelial mesenchymal transition in
colorectal cancer: Seminal role in promoting disease progression
and resistance to neoadjuvant therapy. Surg Oncol. 21:316–323.
2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Sun L, Ke J, He Z, Chen Z, Huang Q, Ai W,
Wang G, Wei Y, Zou X, Zhang S, et al: HES1 promotes colorectal
cancer cell resistance To 5-Fu by inducing Of EMT and ABC
transporter proteins. J Cancer. 8:2802–2808. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Fujikawa H, Tanaka K, Toiyama Y, Saigusa
S, Inoue Y, Uchida K and Kusunoki M: High TrkB expression levels
are associated with poor prognosis and EMT induction in colorectal
cancer cells. J Gastroenterol. 47:775–784. 2012.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Ogino S, Brahmandam M, Cantor M, Namgyal
C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M and Fuchs CS:
Distinct molecular features of colorectal carcinoma with signet
ring cell component and colorectal carcinoma with mucinous
component. Mod Pathol. 19:59–68. 2006.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Kakar S, Deng G, Smyrk CT, Cun L, Sahai V
and Kim SY: Loss of heterozygosity, aberrant methylation, BRAF
mutation and KRAS mutation in colorectal signet ring cell
carcinoma. Mod Pathol. 25:1040–1047. 2012.PubMed/NCBI View Article : Google Scholar
|
